---
title: "The EU plans to restrict Chinese companies from participating in medical device tenders, the latest response from the Ministry of Commerce"
description: "The European Union plans to prohibit Chinese medical device manufacturers from participating in public procurement projects exceeding 5 million euros within the next five years. In response, a spokesp"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/242933589.md"
published_at: "2025-06-03T11:57:02.000Z"
---

# The EU plans to restrict Chinese companies from participating in medical device tenders, the latest response from the Ministry of Commerce

> The European Union plans to prohibit Chinese medical device manufacturers from participating in public procurement projects exceeding 5 million euros within the next five years. In response, a spokesperson for the Ministry of Commerce stated that the EU's decision harms the interests of Chinese enterprises, undermines fair competition, and creates trade barriers. China firmly opposes this and hopes the EU will correct its erroneous practices. China will closely monitor subsequent actions and take measures to safeguard the legitimate rights and interests of Chinese enterprises

According to the Zhitong Finance APP, on June 3rd, in response to the EU's plan to prohibit Chinese medical device manufacturers from participating in EU public procurement projects worth over 5 million euros for the next five years, a spokesperson for the Ministry of Commerce stated that the EU's decision and discriminatory measures not only harm the interests of Chinese enterprises but also undermine fair competition by using unilateral tools and create new trade barriers. China firmly opposes this protectionist practice. It hopes the EU will correct its erroneous actions, and China will closely monitor the EU's subsequent actions and take measures to firmly safeguard the legitimate rights and interests of Chinese enterprises.

## **The transcript is as follows:**

**A spokesperson for the Ministry of Commerce answers reporters' questions regarding the EU's proposed restrictions on Chinese companies' participation in public procurement of medical devices**

Question: Some media reports indicate that EU member states voted to prohibit Chinese medical device manufacturers from participating in EU public procurement projects worth over 5 million euros for the next five years based on the "International Procurement Instrument." What is the Ministry of Commerce's comment on this?

Answer: China has noted the relevant situation. The EU's decision and discriminatory measures not only harm the interests of Chinese enterprises but also undermine fair competition by using unilateral tools and create new trade barriers. China firmly opposes this protectionist practice.

Currently, the global economic order is facing severe shocks from unilateralism and protectionism. As responsible major economies, China and the EU should adhere to WTO rules, uphold fairness, transparency, and non-discrimination principles, respond to challenges through mutual openness, resolve differences through cooperation and dialogue, and jointly maintain the healthy development of China-EU economic and trade relations. China hopes the EU will correct its erroneous actions, and it will closely monitor the EU's subsequent actions and take measures to firmly safeguard the legitimate rights and interests of Chinese enterprises.

This article is compiled from: Ministry of Commerce official website; Edited by Chen Xiaoyi of Zhitong Finance

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 期權熱點｜上周五 UVIX 漲 3%，部分看漲期權飆升 150% | 美東時間 2026-02-13，2 倍做多恐慌指數期貨 ETF 期權總成交 86443 張，看漲期權佔比 82%，看跌期權佔比 17%。 | [Link](https://longbridge.com/en/news/276030214.md) |
| Hi Line Capital Management LLC 在信諾保險集團 $CI 中建立了頭寸 | Hi Line Capital Management LLC 已在信諾保險（NYSE:CI）中獲得新頭寸，購買了 18,338 股，價值約 530 萬美元，使其成為該投資組合中第 23 大持股。其他機構投資者也增加了對信諾的持股。分析師對該 | [Link](https://longbridge.com/en/news/275972854.md) |
| 西氏醫藥服務的利潤率下降至 16.3%，這引發了對其樂觀增長敍述的質疑 | 西氏醫藥服務報告了 2025 財年第三季度的收入為 8.046 億美元，每股收益為 1.94 美元，較 2024 財年第二季度的 7.021 億美元有所增長。然而，利潤率從 17.4% 下降至 16.3%，引發了對未來增長的擔憂，因為 6% | [Link](https://longbridge.com/en/news/275848079.md) |
| Johnson Investment Counsel Inc. 減持了 Zimmer Biomet Holdings, Inc. $ZBH 的股票 | Johnson Investment Counsel Inc. 在第三季度減少了對 Zimmer Biomet Holdings, Inc. 的持股比例，下降了 38.3%，目前持有 28,930 股，價值 285 萬美元。其他機構投資者也 | [Link](https://longbridge.com/en/news/275752492.md) |
| Envoy Medical 簽署了多項融資協議 | Envoy Medical 已簽署多項融資協議，包括一項證券購買協議，通過公開發行普通股和認股權證籌集約 3000 萬美元。此次發行的價格為每股 0.40 美元，涉及內部人士和其他投資者的參與。該公司還聘請 H.C. Wainwright  | [Link](https://longbridge.com/en/news/275951566.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.